These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
515 related articles for article (PubMed ID: 24813066)
1. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property. Velasquez G Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066 [TBL] [Abstract][Full Text] [Related]
2. Global health and Brazilian foreign policy: the negotiations on innovation and intellectual property. Lima JHDS Cien Saude Colet; 2017 Jul; 22(7):2213-2221. PubMed ID: 28724003 [TBL] [Abstract][Full Text] [Related]
3. Trade, TRIPS, and pharmaceuticals. Smith RD; Correa C; Oh C Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054 [TBL] [Abstract][Full Text] [Related]
4. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Oliveira MA; Bermudez JA; Chaves GC; Velásquez G Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916 [TBL] [Abstract][Full Text] [Related]
5. The ethics of intellectual property rights in an era of globalization. Shah AK; Warsh J; Kesselheim AS J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942 [TBL] [Abstract][Full Text] [Related]
6. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights]. Allard Soto R Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827 [TBL] [Abstract][Full Text] [Related]
7. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement. Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726 [TBL] [Abstract][Full Text] [Related]
8. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil. Rosenberg ST Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542 [TBL] [Abstract][Full Text] [Related]
9. Canada and access to medicines in developing countries: intellectual property rights first. Lexchin J Global Health; 2013 Sep; 9():42. PubMed ID: 24007595 [TBL] [Abstract][Full Text] [Related]
10. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards. Cohen-Kohler JC; Forman L; Lipkus N Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618 [TBL] [Abstract][Full Text] [Related]
11. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines. Townsend B; Gleeson D; Lopert R Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239 [TBL] [Abstract][Full Text] [Related]
12. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment. Adekola TA Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136 [TBL] [Abstract][Full Text] [Related]
13. Introduction: Access to life-saving medicines and intellectual property rights. Schroeder D Camb Q Healthc Ethics; 2011 Apr; 20(2):277-8. PubMed ID: 21435302 [No Abstract] [Full Text] [Related]
14. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation. McGIVERN L Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392 [TBL] [Abstract][Full Text] [Related]
15. Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process. Wong ASY; Cole CB; Kohler JC Global Health; 2021 Aug; 17(1):92. PubMed ID: 34416883 [TBL] [Abstract][Full Text] [Related]
16. What is the impact of intellectual property rules on access to medicines? A systematic review. Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250 [TBL] [Abstract][Full Text] [Related]
17. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016. 't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417 [TBL] [Abstract][Full Text] [Related]
18. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries. Spectar JM Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914 [No Abstract] [Full Text] [Related]
19. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines]. Chaves GC; Oliveira MA; Hasenclever L; de Melo LM Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075 [TBL] [Abstract][Full Text] [Related]
20. WHO Intergovernmental Working Group on public health, innovation and intellectual property. Jones TM Lancet; 2010 Jul; 376(9734):21. PubMed ID: 20609985 [No Abstract] [Full Text] [Related] [Next] [New Search]